Experts Explore Emerging Evidence Linking Diabetes and Cancer

ALEXANDRIA, VA, Jun 16 (MARKET WIRE) —
A new consensus statement of experts assembled by the American Diabetes
Association and the American Cancer Society reviews emerging evidence
that suggests cancer incidence is associated with diabetes as well as
certain diabetes risk factors and treatments. The new report reviews the
state of science concerning the association between diabetes and cancer
incidence/prognosis; risk factors common to both diseases; possible
biologic links between diabetes and cancer risk; and whether diabetes
treatments influence the risk of cancer or cancer prognosis. In addition,
the report outlines key unanswered questions for future research.

Diabetes and cancer are common diseases that have a tremendous impact on
health worldwide. Epidemiologic evidence suggests that people with
diabetes are at a significantly higher risk of many forms of cancer. Type
2 diabetes and cancer share many risk factors, but potential biologic
links between the two diseases are not completely understood. Moreover,
evidence from observational studies suggests that some medications used
to treat hyperglycemia are associated with either an increased or reduced
risk of cancer. Against this backdrop, the American Diabetes Association
and the American Cancer Society convened a consensus development
conference in December 2009. After a series of scientific presentations
by experts in the field, the writing group independently developed a
consensus report to address important questions: Is there a meaningful
association between diabetes and cancer incidence or prognosis? What risk
factors are common to both cancer and diabetes? What are possible
biologic links between diabetes and cancer risk? And do diabetes
treatments influence cancer risk or cancer prognosis?

For each of these areas, the authors were asked to address current gaps
in evidence and potential research and epidemiologic strategies for
developing more definitive evidence in the future. Below is a summary of
their findings and recommendations.*

– Diabetes (primarily type 2) is associated with an increased risk of
some cancers (liver, pancreas, endometrium, colon/rectum, breast, and
bladder). Diabetes is associated with a reduced risk of prostate
cancer. For some other cancer sites, there appears to be no
association or the evidence is inconclusive.
– The association between diabetes and some cancers may be due in part
to shared risk factors between the two diseases such as aging,
obesity, diet, and physical inactivity.
– Possible mechanisms for a direct link between diabetes and cancer
include hyperinsulinemia, hyperglycemia, and inflammation.
– Healthy diet, physical activity, and weight management reduce the risk
and improve outcomes of type 2 diabetes and some forms of cancer and
should be promoted for all.
– Patients with diabetes should be strongly encouraged by their health
care professionals to undergo appropriate cancer screenings as
recommended for all people of their age and sex.
– The evidence for specific drugs affecting cancer risk is limited, and
observed associations may have been confounded by indications for
specific drugs, effects on other cancer risk factors such as body
weight and hyperinsulinemia, and the complex progressive nature of
hyperglycemia and pharmacotherapy in type 2 diabetes.
– Although still limited, early evidence suggests that metformin is
associated with a lower risk of cancer and that exogenous insulin is
associated with an increased cancer risk. Further research is needed
to clarify these issues and evaluate the possible association of
insulin and other diabetes medications with the risk of cancer.
– Cancer risk should not be a major factor when choosing between
available diabetes therapies for the average patient. For selected
patients with a very high risk of cancer occurrence (or for recurrence
of specific cancer types), these issues may require more careful
consideration.
– Many research questions remain.

“Traditionally there hasn’t been much overlap between research in
cancer and in diabetes,” says Edward Giovannucci, MD, SCD, co-chair of
the consensus report group. “But recently it’s become clearer that there
are fascinating links between the two. Our summary may raise more
questions than provide answers, but we hope that it will spur additional
studies.”

“The vast majority of patients with diabetes need not consider cancer
risk when weighing their diabetes therapy options,” added David M.
Harlan, MD, co-chair of the consensus report group, “Only patients with a
very high risk for cancer occurrence, or re-occurrence, may wish to
carefully consider their options. Even then, the association appears to
exist for some cancer types, and not for others. We have much to learn.”

*Recommendations in this report are solely the opinions of the authors
and do not represent the official position of the American Diabetes
Association or the American Cancer Society

Article: “Diabetes and Cancer: A Consensus Report.” Edward Giovannucci,
MD, ScD; David M. Harlan, MD; Michael C. Archer, MA, PhD, DSC; Richard M.
Bergenstal, MD; Susan M. Gapstur, PhD; Laurel A. Habel, PhD; Michael
Pollak, MD; Judith G. Regensteiner, PhD; Douglas Yee, MD. Diabetes Care,
Published Online: June 16, 2010; Print Issue Date: July 2010.

Diabetes Care, published by the American Diabetes Association, is the
leading peer-reviewed journal of clinical research into one of the
nation’s leading causes of death by disease. Diabetes also is a leading
cause of heart disease and stroke, as well as the leading cause of adult
blindness, kidney failure, and non-traumatic amputations.

The American Diabetes Association is leading the fight to stop diabetes
and its deadly consequences and fighting for those affected by diabetes.
The Association funds research to prevent, cure and manage diabetes;
delivers services to hundreds of communities; provides objective and
credible information; and gives voice to those denied their rights
because of diabetes. Founded in 1940, our mission is to prevent and cure
diabetes and to improve the lives of all people affected by diabetes. For
more information please call the American Diabetes Association at
1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information
from both these sources is available in English and Spanish.

Contact:
Dayle Kern
(703) 549-1500 ext. 2290
dkern@diabetes.org

Copyright 2010, Market Wire, All rights reserved.

Common blood pressure drugs may raise cancer risk

(Reuters) – A widely used class of blood pressure drugs may slightly increase the risk of cancer, U.S. researchers said on Sunday, and they are calling on U.S. regulators to take a closer look.

Health

They said an analysis of available data on drugs in the class known as angiotensin-receptor blockers showed patients were 1.2 percent more likely to be diagnosed with a new cancer over four years than others who did not take the drugs.

Most patients in the trials (86 percent) took German drugmaker Boehringer Ingelheim’s telmisartan, sold as Micardis, which has annual sales of more than $1.5 billion.

“The increased risk of new cancer occurrence is modest but significant,” Dr. Ilke Sipahi and colleagues from Case Western Reserve University in Cleveland and colleagues wrote in the journal Lancet Oncology.

There were not enough data in the studies to say if individual drugs in the class raise the risk or if it is a so-called class effect shared by all such drugs.

Even so, Dr. Steven Nissen, a cardiologist at the Cleveland Clinic, said in a commentary the findings were “disturbing and provocative, raising crucial drug safety questions for practitioners and the regulatory community.”

He said regulators need to look more closely at the risk of cancer with ARB use and that doctors should be more cautious about prescribing ARBs, and especially Micardis.

Privately held Boehringer Ingelheim defended the safety of its drug, saying in a statement its own “internal safety data analysis of primary data contradicts the conclusions” of an increased cancer risk.

Nissen did a similar analysis that raised alarms about heart risks from GlaxoSmithKline diabetes drug Avandia.

Currently, there are no major safety concerns linked with taking angiotensin-receptor blockers or ARBs, which work by blocking receptors for angiotensin II, a hormone that increases blood pressure.

But a 2003 study in patients with heart failure did find that the drug Atacand, or candesartan, made by the Anglo-Swedish firm AstraZeneca, significantly raised the risk of fatal cancers compared with a dummy pill.

PUBLICLY AVAILABLE DATA

Sipahi and colleagues did a so-called meta-analysis, pooling all publicly available data from randomized trials of ARBs published before November 2009.

Other drugs in the class include Merck & Co’s Cozaar, sold generically as losartan; Diovan or valsartan made by Swiss drug firm Novartis; irbesartan, jointly marketed by Sanofi-Aventi and Bristol-Myers Squibb as Avapro; Daiichi Sankyo’s Benicar or olmesartan; and Solvay Pharmaceuticals’ Teveten or eprosartan.

Overall, they found that patients taking the drugs had 7.2 percent risk of having a new cancer diagnosis, compared with 6 percent risk for patients in the control groups.

When they looked at cancer types, only lung cancer stood out, with 0.9 percent of patients taking blood pressure drugs developing a new lung cancer compared with 0.7 percent of patients in the control arm.

The drugs did not appear to increase the risk of death from cancer, but the team said cancers can develop slowly and cancer deaths might not show up in the relatively short studies.

Just three out of seven FDA-approved drugs — telmisartan, losartan, and candesartan — were studied, and it is not clear what affect other drugs in the class might have on cancers.

Nevertheless, they said given how widely the drugs are used, the risk is worth further study.

Boehringer Ingelheim said its own analysis of data from three large trials showed no increased cancer risk associated with Micardis. But in one study, called ONTARGET, there was a slight increased risk in one treatment arm when the drug was taken in combination with common blood pressure drugs known as ACE-inhibitors, such as ramipril.

The company said the product label does not recommend the drug be used in combination with ACE-inhibitors.

Nissen said the study is limited by the fact that the trials were not designed to look at cancer risks.

But he said the drugs are often overprescribed because of aggressive marketing, and patients might fare just as well taking inexpensive ACE inhibitors instead.

Other experts stressed that patients need to keep taking their blood pressure medications.

“At the moment there isn’t enough evidence to draw any firm conclusions about how blood pressure drugs might affect cancer risk and this will need further investigation,” Martin Ledwick, head information nurse at Cancer Research UK, said in a statement.

(Additional reporting by Kate Kelland in London, editing by Philip Barbara)

Common blood pressure drugs may raise cancer risk

CHICAGO, June 13 (Reuters) – A widely used class of blood pressure drugs may slightly increase the risk of cancer, U.S. researchers said on Sunday, and they are calling on U.S. regulators to take a closer look.

They said an analysis of available data on drugs in the class known as angiotensin-receptor blockers showed patients were 1.2 percent more likely to be diagnosed with a new cancer over four years than others who did not take the drugs.

Most patients in the trials (86 percent) took German drugmaker Boehringer Ingelheim’s telmisartan, sold as Micardis, which has annual sales of more than $1.5 billion.

“The increased risk of new cancer occurrence is modest but significant,” Dr. Ilke Sipahi and colleagues from Case Western Reserve University in Cleveland and colleagues wrote in the journal Lancet Oncology.

There were not enough data in the studies to say if individual drugs in the class raise the risk or if it is a so-called class effect shared by all such drugs.

Even so, Dr. Steven Nissen, a cardiologist at the Cleveland Clinic, said in a commentary the findings were “disturbing and provocative, raising crucial drug safety questions for practitioners and the regulatory community.”

He said regulators need to look more closely at the risk of cancer with ARB use and that doctors should be more cautious about prescribing ARBs, and especially Micardis.

Privately held Boehringer Ingelheim defended the safety of its drug, saying in a statement its own “internal safety data analysis of primary data contradicts the conclusions” of an increased cancer risk.

Nissen did a similar analysis that raised alarms about heart risks from GlaxoSmithKline (GSK.L) diabetes drug Avandia.

Currently, there are no major safety concerns linked with taking angiotensin-receptor blockers or ARBs, which work by blocking receptors for angiotensin II, a hormone that increases blood pressure.

But a 2003 study in patients with heart failure did find that the drug Atacand, or candesartan, made by the Anglo-Swedish firm AstraZeneca (AZN.L), significantly raised the risk of fatal cancers compared with a dummy pill.

PUBLICLY AVAILABLE DATA

Sipahi and colleagues did a so-called meta-analysis, pooling all publicly available data from randomized trials of ARBs published before November 2009.

Other drugs in the class include Merck & Co’s (MRK.N) Cozaar, sold generically as losartan; Diovan or valsartan made by Swiss drug firm Novartis (NOVN.VX); irbesartan, jointly marketed by Sanofi-Aventis (SASY.PA) and Bristol-Myers Squibb (BMY.N) as Avapro; Daiichi Sankyo’s (4568.T) Benicar or olmesartan; and Solvay Pharmaceuticals’ (SOLB.BR) Teveten or eprosartan.

Overall, they found that patients taking the drugs had 7.2 percent risk of having a new cancer diagnosis, compared with 6 percent risk for patients in the control groups.

When they looked at cancer types, only lung cancer stood out, with 0.9 percent of patients taking blood pressure drugs developing a new lung cancer compared with 0.7 percent of patients in the control arm.

The drugs did not appear to increase the risk of death from cancer, but the team said cancers can develop slowly and cancer deaths might not show up in the relatively short studies.

Just three out of seven FDA-approved drugs — telmisartan, losartan, and candesartan — were studied, and it is not clear what affect other drugs in the class might have on cancers.

Nevertheless, they said given how widely the drugs are used, the risk is worth further study.

Boehringer Ingelheim said its own analysis of data from three large trials showed no increased cancer risk associated with Micardis. But in one study, called ONTARGET, there was a slight increased risk in one treatment arm when the drug was taken in combination with common blood pressure drugs known as ACE-inhibitors, such as ramipril.

The company said the product label does not recommend the drug be used in combination with ACE-inhibitors.

Nissen said the study is limited by the fact that the trials were not designed to look at cancer risks.

But he said the drugs are often overprescribed because of aggressive marketing, and patients might fare just as well taking inexpensive ACE inhibitors instead.

Other experts stressed that patients need to keep taking their blood pressure medications.

“At the moment there isn’t enough evidence to draw any firm conclusions about how blood pressure drugs might affect cancer risk and this will need further investigation,” Martin Ledwick, head information nurse at Cancer Research UK, said in a statement.

(Additional reporting by Kate Kelland in London, editing by Philip Barbara)

Scientists find genes linked to testicular cancer

(Reuters) – British scientists have found three new genetic risk factors for testicular cancer, the most common form of the disease in young men, and say their findings should aid efforts for better treatments and earlier diagnosis.

Health

A research team led by the Institute of Cancer Research scanned the gene maps of almost 6,000 men, some with and some without testicular cancer, and found genetic variants in three genetic regions were significantly more common in the cancer patients.

“The genes located in these regions give us clues to the mechanisms by which testicular cancer develops,” said Nazneen Rahman, an ICR professor who worked on the study. “In time this may allow us to develop new treatment options.”

The team confirmed their findings by analyzing another 670 testicular cancer patients and 3,500 men without the disease.

The results, published in the journal Nature on Sunday, take the number of genetic regions associated with testicular cancer risk to six, after earlier studies identified others.

“This study represents further, important progress toward identifying men who are at increased genetic risk of testicular cancer,” said Clare Turnbull, who led the study.

“Finding those men at highest risk may allow early detection or prevention of the disease.”

Testicular cancer is the most common cancer in men aged 15 to 45 years. It is considered one of the most treatable cancers because it usually responds well to chemotherapy, but survivors often have fertility problems after treatment.

The disease has a strong genetic component and men who have a brother affected by testicular cancer have an eight- to tenfold increased risk of developing the disease than men with no family history. These inheritance risks are much higher than in other cancer types, which are generally only two-fold.

The three genes identified by the British team are called TERT, ATF7IP and DMRT1.

Turnbull and colleagues explained in their study that TERT and ATF7IP were important in maintaining the correct length of the ends of chromosomes, which are called telomeres.

Shortened telomeres are known to occur in many cancers and genetic variants in TERT have already been linked to other cancers, including lung, bladder, cervical, pancreatic, skin and prostate cancer.

The third gene found in this study, DMRT1, plays an important role in sex determination and has been implicated in the development of testicular cancer in mice.

Repeated exposure to dental X-rays ups thyroid cancer risk

London, June 4 (ANI): Repeated exposure to dental X-rays increases thyroid cancer risk, a new study has revealed.

Analysing 313 cancer patients, scientists from Brighton, Cambridge and Kuwait found the chances of developing cancer rose with increasing numbers of dental X-rays.

“The public health and clinical implications of these findings are particularly relevant in the light of increases in the incidence of thyroid cancer in many countries over the past 30 years,” the Telegraph quoted Dr Anjum Memon, of the Brighton and Sussex Medical School, as saying.

However, Dr Memon was quick to add that the increasing use of sensitive diagnostic techniques does not necessarily account for the entire increase and that other causes warrant investigation. (ANI)

Cysts to reveal pancreatic cancer risk

Washington, June 4 (ANI): American researchers have come up with a method that could be used to predict whether pancreatic cysts are benign or precursors to invasive cancer.

The study, conducted by researchers from the University of Michigan, Indiana University and Van Andel Research Institute (VARI), has appeared in the Annals of Surgery.

First author Brian Haab, VARI Senior Scientific Investigator, said: “Because of the difficulty in detecting pancreatic cancer in its early stages, most cancers are advanced at the time of diagnosis and recur after removal of the tumor.

“The best hope for a long-term cure may be the detection and removal of these pre-cancerous cysts.”

Peter J. Allen, a physician and researcher specializing in pancreatic, liver, and stomach cancer at Memorial Sloan-Kettering Cancer Center, said: “Dr. Haab and his colleagues have sought to address a very challenging clinical management problem regarding cystic lesions of the pancreas.

“As the use of cross-sectional imaging increases, clinicians are seeing increased numbers of patients with these lesions and it will become imperative to sort out benign from pre-malignant.”

The most common and deadly form of pancreatic cancer, pancreatic ductal adenocarcinomas, develops from three types of cysts.

Although the most prevalent type is too small to be detected, the other two can be found using CT or ultrasound imaging and account for 10 – 15 per cent of pancreatic cancers.

However, current methods can only distinguish pre-cancerous cysts from those that are benign with up to 79 per cent accuracy.

Using fluid from a variety of cyst types, researchers looked for patterns in the variations of carbohydrate structures called glycans to determine if there were any biomarkers that could more accurately distinguish between pre-cancerous and benign cysts.

They found several candidates, some of which could be used in combination to determine cyst type.

Dr. Haab said: “Further study will be needed to validate the clinical value of using glycan variations to differentiate cyst types, but it seems like they are more accurate than current methods.”

Dr. Allen said: “(Dr. Haab”s) identification of variants of MUC-1, MUC-5AC, and MUC-16 (genes) within the cyst fluid of pre-malignant lesions is exciting as our current ability to non-operatively define these lesions is limited.

“Hopefully with larger numbers of patients these results can be validated and be put into clinical use.” (ANI)

Binge drinking ‘can increase pancreatic cancer risk’

Washington, May 20 (ANI): A new research from UT Southwestern Medical Center suggests that heavy alcohol use and binge drinking can increase the risk of pancreatic cancer in men.

Researchers found that men who consumed alcohol increased their risk of pancreatic cancer by 1.5 to 6 times compared with those who didn”t consume alcohol or who had less than one drink per month.

Also, men who engaged in binge drinking had a 3.5 times greater likelihood of developing pancreatic cancer.

“If this relationship continues to be confirmed, reducing heavy and binge drinking may be more important than we already know,” said Dr. Samir Gupta, assistant professor of internal medicine at UT Southwestern and lead author of the study, which was conducted at the University of California, San Francisco.

Researchers defined one drink as a can, bottle or 12 ounces of beer; a 4-ounce glass of wine; or one shot of liquor – each serving contains about 14 grams of alcohol.

The heaviest drinkers consumed 21 to 35 drinks per week. Binge drinking was defined as consuming five or more drinks during one drinking session.

However, because women don’t consume as much alcohol as men, researchers did not find the same association amongst them.

This study about the relation between pancreatic cancer and alcohol is different and more detailed because the researchers considered other multiple factors which weren’t taken into account earlier.

In the current study, researchers used structured questionnaires to interview pancreatic cancer patients in the San Francisco area diagnosed between 1995 and 1999 and compared those results with those of control participants matched by sex, age and county of residence.

The 532 cancer patients ranged in age from 21 to 85, with the majority between 60 and 80 years of age. Fifty-five percent of study participants were men; 83 percent of them were Caucasian; and most of them were of normal weight with some college education. The 1,701 control participants were of similar demographics.

Cancer of the pancreas, an organ important for digestion and production of hormones, has the lowest overall five-year survival rate of all specific cancers. Early signs of pancreatic cancer are difficult to diagnose, partly because the organ is located deep in the upper abdomen. Mortality rates have changed little in the past three decades, according to the National Cancer Institute.

This study is available online in Cancer Causes and Control. (ANI)

Radiation from full-body airport scanners may increase cancer risk

Melbourne, May 19 (ANI): Scientists in the U.S. have issued a warning that radiation from controversial full-body airport scanners could lead to an increased risk of skin cancer – particularly in kids.

David Agard, University of California biochemist, said that unlike other scanners, the radiation from these devices is delivered at low energy beam levels, with most of the dose concentrated in the skin and underlying tissue.

“While the dose would be safe if it were distributed throughout the volume of the entire body, the dose to the skin may be dangerously high,” News.com.au quoted Agard as saying.

“Ionizing radiation such as the X-rays used in these scanners have the potential to induce chromosome damage, and that can lead to cancer,” Agard added.

Another major concern is that a failure in the device – like a power or software glitch – can lead to an intense radiation dose to a single spot on the skin. (ANI)

Fruits, vegetables ‘can cut child cancer risk’

London, May 10 (ANI): Children must eat more fruits and vegetables to reduce the risk of cancer in later life, a charity has said.

The latest published Health Survey for England (HSE) for 2008 suggested that four in five children are not eating the recommended amount of fruit and vegetables.

Now the World Cancer Research Fund has warned that this could lead to an increased risk of them developing cancer in later life.

“The fact that only a fifth of children are getting enough fruit and vegetables is a concern because it is important that we encourage children to get into healthy habits as early in life as possible,” the Daily Express quoted Nathalie Winn, nutritionist for the WCRF, as saying.

“This is because scientific research shows that eating a plant-based diet with plenty of fruits and vegetables, wholegrains and pulses probably reduces the risk of a number of types of cancer later in life,” Winn added.

Ahead of its annual Fruity Friday campaign, the WCRF is highlighting the importance of a good diet.

The research shows that, on average, boys aged five to 15 eat 3.1 portions of fruit and vegetables while girls have 3.3 portions a day, according to the Health Survey for England 2008.

It even showed that one in 14 boys and one in 25 girls did not eat any fruit or vegetables at all on the day of the survey. (ANI)

Milk-renal cell cancer risk: No concrete proof

Washington, May 6 (ANI): A study has cast doubt on previous research that suggested drinking milk was related to factors that may increase the risk of renal cell cancer.

“The data in this study provide no concrete evidence of a need to alter milk drinking in any way,” said lead researcher Nicholas Timpson, Ph.D., lecturer in genetic epidemiology at the MRC CAiTE Center in the department of social medicine at the University of Bristol, United Kingdom. “If anything, the failure of genetic findings to replicate the association between milk and renal cell cancer suggests that fears that milk consumption might elevate cancer risk are likely to be unfounded.”

These study results are published in the May issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

Previously reported studies suggested a connection between milk intake and renal cell carcinoma risk, and whether this represents a causal association or is the result of bias is currently unclear. Timpson and colleagues used a genetic marker to try to help untangle this observation.

From 1999 through 2003 the researchers conducted a large, hospital-based, case-control study from four central and eastern European countries.

Using observational, genetic and phenotypic data, they determined whether the genetic variant at the gene MCM6 — known to be associated with lactose tolerance — may be used as a non-confounded and unbiased marker for milk consumption”s link to cancer risk.

For adult milk drinkers vs. non-milk drinkers in this study, the difference in the odds of renal cell carcinoma was approximately 35 percent. However, when assessing the relationship in a more direct way by using genetic data there was no association between the two.

“We found evidence for the often-questioned relationship between milk consumption and cancer, yet when we used genotypes to verify this relationship, there was no corroboratory evidence,” Timpson said. “This does suggest that the basic findings may be subject to the kinds of biases and inaccuracies that often upset epidemiological research, but that this study would need to be undertaken on a much larger scale in order to verify these initial findings.”

Johanna Lampe, Ph.D., an editorial board member of Cancer Epidemiology, Biomarkers & Prevention who is not associated with this study, said this study demonstrates the complexities of evaluating dietary exposures and cancer risk.

“These results are a reminder to proceed with caution when interpreting data that suggest an association between intake of specific foods and risk of a particular cancer. Human diet is complex and typically involves adherence to certain dietary patterns that are also tied to other lifestyle behaviors,” said Lampe, full member and nutrition scientist in the division of public health sciences at Fred Hutchinson Cancer Research Center, Seattle, Wash. (ANI)

High doses of vitamins C and E may raise cancer risk

Washington, May 5 (ANI): High doses of antioxidant nutritional supplements, such as vitamins C and E, could induce genetic abnormalities in cells, according to a study.

And these abnormalities could predispose supplement-takers to developing cancer, said Dr. Eduardo Marban director of the Cedars-Sinai Heart Institute, lead author of the study.

The researchers accidentally discovered the danger of excessive antioxidant doses while seeking a way to reduce the genetic abnormalities that occurred naturally when the scientists sought to multiply human cardiac stem cells.

Marban stressed that the study”s finding applies only to excessive nutritional supplements and not to foods that are rich in antioxidants, such as milk, oranges, blueberries and peanuts.

Recently, multiple studies have touted the benefits of foods rich in antioxidants.

“Taking one multivitamin daily is fine, but a lot of people take way too much because they think if a little is good, a lot must be better. That is just not the case. If you are taking 10 or 100 times the amount in a daily multivitamin, you may be predisposing your cells to developing cancer, therefore doing yourself more harm than good,” said Marban.

The researchers were disappointed with the higher concentration of oxygen in lab-grown stem cells, which resulted in 9 percent of the cells being rejected because of genetic abnormalities.

“We sought to counter that oxidation problem by adding high doses of antioxidants directly to the cells. That”s when we made the serendipitous discovery that there is a danger zone for the cells exposed to antioxidants to develop genetic abnormalities that predispose to cancer,” said Marban.

Now, Marban is leading an ongoing, groundbreaking clinical trial in which heart attack patients undergo two minimally-invasive procedures in an effort to repair and re-grow healthy muscle in a heart injured by a heart attack.

First, a biopsy of each patient”s own heart tissue is used to grow specialized heart stem cells.

About a month later, the multiplied stem cells are then injected back into the patient”s heart via a coronary artery.

The two-step procedure was completed on the first patient in June 2009. The results of the trial are expected in early 2011.

The study was published in the medical journal Stem Cells. (ANI)

Coffee may help cut uterine cancer risk

Washington May 4 (ANI): Two cups of coffee a day can lower the risk of uterine cancer, claims Mayo Clinic research.

Uterine cancer is the most common cancer for women”s reproductive organs.

According to the American Cancer Society, last year, 42,160 new cases were diagnosed, and it caused 7,780 deaths.

The research found that, among the 20,000 women who participated, those who drank more than two-and-a-half cups of coffee daily were less likely to develop uterine, or endometrial, cancer as compared to women who did not drink coffee at all, reports CBS. (ANI)

Breast cancer survivors at increased second cancer risk if they smoke

Washington, May 3 (ANI): A study has found that women who survive early-stage breast cancer have an increased chance of developing a new second cancer in their other breast or elsewhere if they smoke.

Investigators from The Cancer Institute of New Jersey (CINJ) are releasing these findings at an oral presentation during the 92nd Annual Meeting of the American Radium Society taking place this week in Cancun, Mexico.

CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

It has been shown that women who survive breast cancer have two- to six-times increased risk of developing cancer in their other breast, compared with women who have never had breast cancer.

In hopes of making second cancers less likely, researchers have studied risk factors that can be controlled, such as smoking, obesity and alcohol consumption.

This latest study focused on female smokers with early-stage breast cancer who had breast-conserving therapy to remove their disease.

Breast conserving therapy is the standard treatment given to most patients with early-stage disease and consists of a lumpectomy followed by radiation therapy to the breast.

Data were analysed from 796 self-reported smokers who received breast-conserving therapy between 1975 and 2007 at Yale University School of Medicine.

The team found that at 15 years post-treatment, the risk of developing a new second cancer was significantly greater in smokers compared to non-smokers (25 percent versus 19 percent).

The study also found that smokers had a greater risk of developing cancer in the other breast than those who did not smoke (13 percent versus eight percent) 15 years following treatment.

While correlation was made to other prognostic factors, including age, family history, hormone receptor status and HER2/neu status, smoking was found to be independent of these other indicators.

CINJ Associate Director, Bruce G. Haffty, MD, professor and chair of the Department of Radiation Oncology at UMDNJ-Robert Wood Johnson Medical School, is the senior investigator.

“We believe this study looks at the largest subgroup of women to date on this topic. These new data are significant in that they show women can exercise some control over a known risk factor for developing a new second cancer,” he noted.

The findings are being presented at the annual meeting by Amar Rewari, MD, MBA, who is a resident in Dr. Haffty”s department.

Other collaborators include Sharad Goyal, MD, CINJ and UMDNJ-Robert Wood Johnson Medical School and Meena Moran, MD, Yale University School of Medicine.

Conflicting results on this subject recently appeared in studies published in the Journal of Clinical Oncology and the American Journal of Epidemiology. (ANI)

Resetting biological clock may stop breast cancer in its tracks

Washington, April 28 (ANI): Scientists have found that a form of the element selenium, which is found in tiny amounts in people”s diets, can help reset a cell”s biological clock after it has been thrown off by cancer-causing chemicals.

According to researchers, this discovery could lead to a way to help the body reboot cells that are disrupted by cancerous agents and potentially stop breast cancer in its tracks.

At issue is the biological clock, or circadian rhythm, which affects how your body works, even down to the cellular level. Studies have already shown that the circadian rhythm can be interrupted through gene manipulation, shift work that involves exposure to light at night and exposure to cancer-causing chemicals.

In the new study, a research team from the Cancer Institute of New Jersey and the Environmental & Occupational Health Sciences Institute (which is jointly administered by UMDNJ-Robert Wood Johnson Medical School and Rutgers, the State University of New Jersey) performed a lab experiment in which they exposed mammary cells to a single dose of a cancer-causing chemical.

The biological clock in the cells was disrupted, but was reset and restored after treatment with the form of selenium.

“These findings are significant because they show how disruption of circadian rhythm can increase the risk of mammary cancer risk, and how a simple dietary supplement can reverse this effect, restore rhythm, and reduce cancer incidence, at least in experimental models,” Helmut Zarbl, associate director for public health science at the Cancer Institute of New Jersey, said.

The researchers have launched a related study to examine how shift work — which resets the body”s biological clock – disrupts how cells operate.

The study has been published in the online edition of Cancer Prevention Research. (ANI)

Need to prevent periodontitis to cut head and neck cancer risk

Washington, Sep 8 (ANI): Researchers at the University of Buffalo have stressed on the need for increased efforts to prevent and treat chronic periodontitis, a form of gum disease, to reduce the risk for head and neck cancer.

Led by Dr. Mine Tezal at Buffalo, periodontitis is an independent risk factor for head and neck squamous cell carcinoma.

“Prevent periodontitis; if you have it already, get treatment and maintain good oral hygiene,” said Tezal.

Chronic periodontitis is characterized by progressive loss of the bone and soft tissue attachment that surround the teeth.

The researchers assessed the role of chronic periodontitis on head and neck squamous cell carcinoma, as well as the individual roles on three subsites: oral cavity, oropharyngeal and laryngeal.

They used radiographic measurement of bone loss to measure periodontitis among 463 patients, 207 of whom were controls.

The results of the study revealed that chronic periodontitis might represent a clinical high-risk profile for head and neck squamous cell carcinoma.

The strength of the association was greatest in the oral cavity, followed by the oropharynx and larynx, according to Tezal.

When they stratified the relationship by tobacco use, they found that the association persisted in those patients who never used tobacco.

The researchers did not expect the periodontitis-head and neck squamous cell carcinoma association to be weaker in current smokers compared to former and never smokers, according to Tezal.

However, this interaction, although statistically significant, was not very strong.

“Confirmatory studies with more comprehensive assessment of smoking, such as duration, quantity and patterns of use, as well as smokeless tobacco history are needed,” said Tezal.

“Our study also suggests that chronic periodontitis may be associated with poorly differentiated tumor status in the oral cavity. Continuous stimulation of cellular proliferation by chronic inflammation may be responsible for this histological type. However, grading is subjective and we only observed this association in the oral cavity. Therefore, this association may be due to chance and needs further exploration,” she added.

Andrew Olshan, Ph.D., said these results lend further support to the potential importance of poor oral health in this form of cancer.

Olshan said, “Although the study is comparatively small, the researchers were able to also see an association between bone loss and the risk of head and neck cancer.”

The results of the study have been published in Cancer Epidemiology, Biomarkers and Prevention, a journal of the American Association for Cancer Research. (ANI)

Hepatitis B virus mutations may help predict liver cancer risk

Washington, July 3 (ANI): Scientists from Second Military Medical University in Shanghai have revealed that mutations in the DNA of hepatitis B virus (HBV) might help predict which patients are at increased risk of developing liver cancer,

HBV infection is a known cause of hepatocellular carcinoma (HCC), the most common form of liver cancer.

During the research, the team analysed 43 studies with a total of 11,582 HBV-infected participants, of whom 2,801 had HCC.

They found that certain mutations were associated with development of HCC, and more prevalent as chronic HBV infection progressed from the asymptomatic state to liver cirrhosis or HCC.

“Frequent examination of patients with chronic HBV infections for the presence of these mutations may be useful for identifying which patients require preventive antiviral treatment and for the prediction of HCC,” wrote the authors.

The study appears in Journal of the National Cancer Institute. (ANI)

Vegetarians develop ‘fewer’ cancers

London, July 1 (ANI): Vegetarians may be less likely than meat eaters to develop cancers of the blood, bladder and stomach, suggests a study.

Lead researcher Professor Tim Key, however, insists that this may not be the case for all forms of the disease.

Scientists from universities in the UK and New Zealand examined 61,566 British men and women, including meat-eaters, those who ate fish but not meat, and those who did not ate either.

The researchers found that while nearly 33 people in 100 in the general population would develop cancer during their lifetime, for those who abstained from meat the risk was reduced to about 29 in 100.

The study discovered considerable differences between meat-eaters and vegetarians in the propensity to cancers of the lymph and the blood, with the latter just over half as likely to develop these forms of the disease.

Vegetarians were observed to get notably fewer of stomach, bladder, non-Hodgkin’s lymphoma and multiple myeloma cancers.

But Key warned that the findings, published in the British Journal of Cancer, were not strong enough to draw absolute conclusions.

“At the moment these findings are not strong enough to ask for particularly large changes in the diets of people following an average balanced diet,” the BBC quoted Key as saying.

A spokesperson for Cancer Research UK, which funded the research, added: “These interesting results add to the evidence that what we eat affects our chances of developing cancer. We know that eating a lot of red and processed meat increases the risk of stomach cancer.

But the links between diet and cancer risk are complex and more research is needed to see how big a part diet plays and which specific dietary factors are most important.”

Myeloma UK also said: “Dietary advice to myeloma patients remains aligned with national guidance – that they should eat a healthy, balanced diet high in fibre, fruit and vegetables and low in saturated fat, salt and red and processed meat.”

Dr Panagiota Mitrou, Science and Research Programme Manager for the World Cancer Research Fund, further said: “The suggestion that vegetarians might be at reduced risk of blood cancers is particularly interesting. However, this finding should be treated with caution since not much is known about the link between diet and these types of cancer. Further studies of vegetarians are needed before we can be confident this is actually the case.” (ANI)

Purple sweet potato may help fight cancer

Washington, June 30 (ANI): A purple sweet potato developed by Kansas State University researchers has been found to have increased amount of anti-cancer components.

K-State’s Soyoung Lim, doctoral student in human nutrition, Manhattan has revealed that purple sweet potatoes have high contents of anthocyanin, which is a pigment that presents the purple colour in the vegetable.

The pigment can produce red, blue and purple colours depending on the source’s chemical structure, such as in foods like blueberries, red grapes and red cabbage.

According to Lim, anthocyanins have been epidemiologically associated with a reduced cancer risk, but the anti-cancer ability of the purple sweet potato has not been well investigated.

During the study, the researchers analysed three different purple sweet potatoes that had varying amounts of anthocyanin.

To quantify the amount in each potato, Lim extracted pigments from the vegetables and injected them into an HPLC-MS Analysis, which she said is a method that separates components.

The potatoes were segregated by multiple traits based on flesh pigmentation and fibre contents.

The study showed that Kansas-bred potato had significantly higher anthocyanin contents compared to the other potatoes.

The researchers also found two derivatives of anthocyanin that were dominant: cyanidin and peonidin.

The specially bred purple sweet potato had a much higher total phenolic content and antioxidant capacity than the other regularly occurring purple sweet potatoes.

Phenols are chemical compounds that have been found to have anti-aging and antioxidant components.

For further study, Lim treated human colon cancer cells with low concentrations of the pigment derivatives cyanidin and peonidin and found that the treatment led to significant cell growth inhibition for the cancer cells.

The findings were presented at Experimental Biology Meeting. (ANI)

Insulin analogue glargine linked to increased cancer risk among diabetes Patients

Washington, June 27 (ANI): Diabetes patients’ risk of cancer increases if they use the long-acting insulin analogue glargine instead of human insulin, according to a study.

Led by a collaborative team of researchers from the Institute for Quality and Efficiency in Health Care (IQWiG) and a research institute of the German Local Health Care Fund, the study analysed the data of almost 130,000 patients with diabetes in Germany who had been treated with either human insulin or the insulin analogues lispro (trade name: Humalog), aspart (Novorapid) or glargine (Lantus) between January 2001 and June 2005.

Writing about their study in the journal Diabetologia, the official organ of the European Association for the Study of Diabetes (EASD), the researchers say that the disturbing result is that malignancies were found more frequently in patients treated with glargine than in those prescribed a comparable dose of human insulin.

“Our analysis does not provide absolute proof that glargine promotes cancer. Our study does, however, arouse an urgent suspicion which should have consequences for the treatment of patients,” says Peter T. Sawicki, IQWiG’s Director and co-author of the study.

The researchers have revealed that no difference was found between the short-acting insulin analogues, lispro and aspart, and human insulin.

Insulin analogues are synthetic molecules that do not occur naturally, whereas human insulin matches the insulin that the human body manufactures itself.

The study also revealed that the risk of cancer rose further with increasing glargine dose when compared to human insulin.

The researchers say that the dose-dependent relationship with glargine also confirms the suspicion that the drug plays a causal role.

However, add the research team, the latest study is no reason for patients with diabetes to change their treatment hastily, especially if the glargine dose used is low.

Diabetes is a complex disease and many aspects need to be considered in its treatment.

“However, if a patient can be treated equally well with human insulin as with glargine, then, after consultation with his or her doctor, the patient should consider changing to human insulin. If at all possible, patients with an increased risk of cancer should use human insulin instead of glargine,” says Sawicki.

The researchers have no evidence that glargine or other insulin agents transform normal cells to cancer cells.

However, it may be possible that glargine stimulates the growth of existing cancer cells more strongly than other types of insulin, they add. (ANI)

Eating animal fat may raise pancreatic cancer risk

Washington, June 27 (ANI): A high-fat diet full of red meat and dairy products can increase the risk of pancreatic cancer, says a new study.

The research has been published online June 26 in the Journal of the National Cancer Institute.

To reach the cocnlsuion, Rachael Z. Stolzenberg-Solomon, Ph.D., of the Division of Cancer Epidemiology and Genetics at the National Cancer Institute in Bethesda, Md., and colleagues analyzed a cohort of over 500,000 people from the National Institutes of Health – AARP Diet and Health Study.

Participants completed a food frequency questionnaire in 1995 and 1996 and were followed prospectively for an average of 6 years to track a variety of health outcomes, including pancreatic cancer.

Men and women who consumed high amounts of total fats had 53 percent and 23 percent higher relative rates of pancreatic cancer, respectively, compared with men and women who had the lowest fat consumption.

Participants who consumed high amounts of saturated fats had 36 percent higher relative rates of pancreatic cancer compared with those who consumed low amounts.

“[W]e observed positive associations between pancreatic cancer and intakes of total, saturated, and monounsaturated fat overall, particularly from red meat and dairy food sources. We did not observe any consistent association with polyunsaturated or fat from plant food sources,” the authors write.

“Altogether, these results suggest a role for animal fat in pancreatic carcinogenesis,” they added. (ANI)